This is therefore a contrasting of the dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation in Esperion Therapeutics Inc. (NASDAQ:ESPR) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS). The two are both Biotechnology companies that compete with one another.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Esperion Therapeutics Inc.||46||8.61||N/A||-7.54||0.00|
|Ionis Pharmaceuticals Inc.||67||11.94||N/A||2.58||25.76|
Table 1 highlights Esperion Therapeutics Inc. and Ionis Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.
Table 2 demonstrates the net margins, return on assets and return on equity of Esperion Therapeutics Inc. and Ionis Pharmaceuticals Inc.
|Net Margins||Return on Equity||Return on Assets|
|Esperion Therapeutics Inc.||0.00%||-48.6%||-35.7%|
|Ionis Pharmaceuticals Inc.||0.00%||39.3%||14.4%|
Volatility and Risk
A beta of 1.98 shows that Esperion Therapeutics Inc. is 98.00% more volatile than S&P 500. In other hand, Ionis Pharmaceuticals Inc. has beta of 2.32 which is 132.00% more volatile than S&P 500.
Esperion Therapeutics Inc.’s Current Ratio is 3.9 while its Quick Ratio is 3.9. On the competitive side is, Ionis Pharmaceuticals Inc. which has a 9.4 Current Ratio and a 9.4 Quick Ratio. Ionis Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Esperion Therapeutics Inc.
Esperion Therapeutics Inc. and Ionis Pharmaceuticals Inc. Ratings and Recommendations are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Esperion Therapeutics Inc.||0||3||3||2.50|
|Ionis Pharmaceuticals Inc.||0||2||1||2.33|
$69.17 is Esperion Therapeutics Inc.’s consensus price target while its potential upside is 48.66%. Ionis Pharmaceuticals Inc. on the other hand boasts of a $68.33 consensus price target and a 6.73% potential upside. The results from earlier shows that analysts view suggest that Esperion Therapeutics Inc. seems more appealing than Ionis Pharmaceuticals Inc.
Institutional & Insider Ownership
Esperion Therapeutics Inc. and Ionis Pharmaceuticals Inc. has shares held by institutional investors as follows: 0% and 85.4%. Esperion Therapeutics Inc.’s share held by insiders are 2.4%. Competitively, insiders own roughly 0.2% of Ionis Pharmaceuticals Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Esperion Therapeutics Inc.||-2.95%||17.72%||5.18%||-10.13%||19.79%||6.46%|
|Ionis Pharmaceuticals Inc.||-3.06%||-20.66%||9.91%||29.22%||43.49%||23.1%|
For the past year Esperion Therapeutics Inc. was less bullish than Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. beats Esperion Therapeutics Inc. on 8 of the 10 factors.
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.